Psyllium: Cholesterol and Heart Health

Table of Contents

1. In Short
2. How a Gel Lowers Cholesterol
3. The 28-Trial Meta-Analysis
4. The 2024 Plantago Meta-Analysis
5. Thirty Years of Consistent Results
6. Psyllium Added to Statins
7. What the FDA Health Claim Says
8. Triglycerides, HDL and Blood Pressure
9. What the Evidence Cannot Yet Say
10. Key Research Papers
11. Connections

In Short

• The size of the effect: LDL cholesterol about 0.33–0.35 mmol/L lower (roughly 13 mg/dL) in pooled trials, with total cholesterol also lower and HDL unchanged.
• The dose studied: a median of about 10.2 g of psyllium a day in the largest meta-analysis.
• The quality: moderate for LDL and high for apolipoprotein B, according to the GRADE assessment in that meta-analysis.
• The regulators: an FDA-authorised heart-disease health claim (7 g of soluble fibre from psyllium husk a day) and an EMA indication as an adjuvant to diet in high cholesterol.
• The gap: no trial has measured heart attacks, strokes or deaths. The EMA states this directly.

How a Gel Lowers Cholesterol

Psyllium is not absorbed, so it cannot act on the liver directly. Its effect starts in the small intestine.

A 2017 review of fibre physics by McRorie and McKeown reports that the cholesterol-lowering effect of soluble fibres is “highly correlated with the viscosity” of the fibre. Gel-forming fibres — psyllium, beta-glucan from oats and barley, raw guar gum — lower cholesterol in trials. Soluble fibres that do not form a gel (inulin, fructo-oligosaccharides, wheat dextrin) and insoluble fibres (wheat bran) do not.

The explanation usually given in the fibre literature is the bile-acid cycle. The liver makes bile acids from cholesterol and releases them into the gut to digest fat; most are normally reabsorbed lower down and recycled. A thick gel traps some of those bile acids and carries them out in the stool. To replace them, the liver draws more cholesterol out of the blood, and LDL levels fall. The site's bile acids animation shows the cycle that this interrupts.

That mechanism has two practical consequences that the trials bear out. First, the effect depends on the gel: fibres that do not thicken do not work this way. Second, it is dose-dependent and modest: a fibre can only remove so much bile acid from the gut each day.

The 28-Trial Meta-Analysis

The most-cited modern analysis is Jovanovski and colleagues' 2018 systematic review and meta-analysis in the American Journal of Clinical Nutrition, from a Toronto clinical-nutrition group. It searched the major databases up to October 2017 and included randomised controlled trials of at least three weeks, in people with or without high cholesterol.

• Trials and people: 28 trials, 1,924 participants.
• Dose: a median of about 10.2 g of psyllium a day.
• LDL cholesterol: −0.33 mmol/L (95% confidence interval −0.38 to −0.27).
• Non-HDL cholesterol: −0.39 mmol/L (−0.50 to −0.27).
• Apolipoprotein B: −0.05 g/L (−0.08 to −0.03).
• Certainty (GRADE): moderate for LDL and non-HDL, downgraded for inconsistency between trials; high for apolipoprotein B.

Non-HDL cholesterol and apolipoprotein B are worth a word. Both capture all the cholesterol-carrying particles that can enter artery walls, not only LDL, which is why the authors called them “alternative lipid targets”. That psyllium moved all three in the same direction makes the finding harder to dismiss as a quirk of one measurement. The authors concluded that psyllium improved both conventional and alternative lipid markers in people with or without high cholesterol.

For readers who want to see their own numbers in context, the Lipid Panel page explains each of these measurements.

The 2024 Plantago Meta-Analysis

A second, independent group at Jilin University pooled trials of Plantago consumption more broadly, up to August 2023.

• Trials and people: 29 randomised trials, 2,769 participants.
• Total cholesterol: 0.28 mmol/L lower than control.
• LDL cholesterol: 0.35 mmol/L lower.
• HDL and triglycerides: no substantial effect.
• Which preparations: total and LDL cholesterol were significantly lower in people taking Plantago husk or psyllium.
• Who: in subgroup analyses, total cholesterol fell significantly in studies including men, healthy people, and people with lipid disorders.

The authors translated the LDL reduction into an estimated 7% lower risk of cardiovascular events. That figure is a calculation based on how LDL relates to heart disease in other research — it was not observed in psyllium trials, none of which counted events.

Thirty Years of Consistent Results

The modern meta-analyses agree closely with older ones, which is part of what makes this finding credible.

Psyllium cereals, 1997

A 1997 meta-analysis of 12 trials (8 published, 4 unpublished) in 404 adults with mild to moderate high cholesterol, all on a low-fat diet, found that a psyllium-enriched cereal lowered total cholesterol by 0.31 mmol/L (5%) and LDL by 0.35 mmol/L (9%) more than a control cereal, with HDL unaffected. Sex, age and menopausal status made no difference. The lead author worked for a breakfast-cereal manufacturer, and the search included contacting food companies involved in psyllium research — a reason to read it alongside the independent analyses above, which found almost the same LDL figure.

All soluble fibres, 1999

A Harvard group pooled 67 controlled trials of pectin, oat bran, guar gum and psyllium. Each gram of soluble fibre (in the range 2–10 g a day) lowered LDL by about 0.057 mmol/L, and the effects of oat, psyllium and pectin were not significantly different from one another. Triglycerides and HDL did not change. The authors' own conclusion was cautious: the effect is “small within the practical range of intake”, and increasing soluble fibre “can make only a small contribution” to cholesterol-lowering diet therapy.

Breakfast cereals, 2014

A systematic review of 232 articles on breakfast cereals graded the evidence that oat-, barley- or psyllium-based cereals help lower cholesterol at grade A, its highest level (“can be trusted to guide practice”).

Foods ranked, 2021

An umbrella review of 108 systematic reviews and 37 guidelines from Sweden graded foods high in soluble fibre, such as oats, barley and psyllium, as causing at least moderate (0.20–0.40 mmol/L) LDL reductions with high certainty — the same tier as plant sterols and replacing saturated fat with unsaturated oils.

Psyllium Added to Statins

Statins lower LDL much more than any fibre does. The question one meta-analysis asked was whether psyllium adds anything on top.

Brum and colleagues (2018) found three randomised controlled trials, lasting 4 to 12 weeks, that gave psyllium alongside a statin and compared it with the statin alone. Pooled, the combination lowered cholesterol significantly more (p = 0.001), and the authors reported that adding psyllium produced an LDL reduction “equivalent to doubling the statin dose”.

Three points of context matter here:

• Only three short trials were available.
• Three of the five authors worked for a company that makes a psyllium product; the other two were at an academic medical centre.
• The abstract reports the comparison with a doubled statin dose but not the size of the extra LDL reduction in mmol/L.

The finding is consistent with the mechanism: statins reduce how much cholesterol the liver makes, while a bile-acid-trapping gel increases how much the liver uses, so the two act at different points. Changes to any cholesterol medicine are a matter for the prescriber; the EMA monograph also notes that use as an adjuvant in high cholesterol “requires medical supervision”. The site's Cholesterol Management page covers medicines and diet together.

What the FDA Health Claim Says

In the United States a food label may only link a nutrient to reduced disease risk if the FDA has authorised that specific claim. Soluble fibre from psyllium husk is one of the few that has been authorised. The rule, 21 CFR 101.81, sets out the details:

• The claim: diets low in saturated fat and cholesterol that include soluble fibre from certain foods may reduce the risk of heart disease; the fibre helps lower blood total and LDL cholesterol.
• The amount: 7 g or more a day of soluble fibre from psyllium seed husk (compared with 3 g of beta-glucan from whole oats or barley, the other eligible source).
• Per serving: a labelled food must provide at least 1.7 g of psyllium soluble fibre per serving.
• Purity: the husk must be at least 95% pure, with limits on protein and foreign matter.
• Species: the husk of Plantago ovata (blond or Indian psyllium), P. indica or P. psyllium.

The same regulations require a psyllium food carrying the claim, if it contains dry or incompletely hydrated husk, to tell consumers it is to be eaten with adequate fluid, to warn of choking, and to tell people with swallowing difficulty not to eat it (21 CFR 101.17(f)). The heart claim and the choking warning come as a pair.

Note what the claim is not: it is a statement about diets and risk, made in the context of a low-saturated-fat diet. It does not say psyllium treats heart disease, and it was not based on trials counting heart attacks.

Triglycerides, HDL and Blood Pressure

• HDL: unchanged in the 1997, 1999 and 2024 meta-analyses. Psyllium does not raise “good” cholesterol.
• Triglycerides: not changed in the general-population meta-analyses (1999, 2024), but lower in people with type 2 diabetes. A 2020 meta-analysis of 8 trials in diabetes reported lower triglycerides and LDL, with very high heterogeneity; a small Italian study of 40 people with type 2 diabetes on sulfonylureas found triglycerides fell after 2 months in the psyllium group but not in the diet-only group.
• Blood pressure: a 2020 meta-analysis of 11 trials (592 participants) found systolic blood pressure 2.04 mmHg lower with psyllium, with a larger effect in people who started higher. The authors were enthusiastic; the absolute size is small.
• Other fibres in diabetes: a 2023 network meta-analysis of 46 trials ranked galactomannans (guar-type gums) first for lowering LDL and triglycerides in type 2 diabetes, so psyllium is not the only, or necessarily the strongest, option in that group.

What the Evidence Cannot Yet Say

• No outcome trials. The EMA monograph states that investigations of ispaghula husk's effect on cardiovascular events and total mortality “are not available” (EMA). The heart benefit is inferred from LDL.
• Inconsistency. The largest meta-analysis downgraded its LDL finding to moderate quality because trials disagreed on the size of the effect.
• Industry involvement. The 1997 cereal meta-analysis and the 2018 statin meta-analysis had industry authors. Independent analyses (1999, 2018 Toronto, 2024 Jilin, 2021 Sweden) reach very similar LDL figures, which reduces — but does not remove — the concern.
• Scale. As the 1999 authors put it, the effect is small within the practical range of intake. It is in the same range as other diet changes, not in the range of a statin.
• Diet context. Many trials were run alongside a low-fat or controlled diet, and the FDA claim is framed in that context.

Key Research Papers

1. Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. The American journal of clinical nutrition. 2018;108(5):922-932. — 28 trials, 1,924 people; LDL, non-HDL cholesterol and apoB all lower; moderate-to-high certainty. PubMed PMID: 30239559
2. Zhu R, Lei Y, Wang S, et al. Plantago consumption significantly reduces total cholesterol and low-density lipoprotein cholesterol in adults: A systematic review and meta-analysis. Nutrition research (New York, N.Y.). 2024;126:123-137. — 29 trials, 2,769 people; total and LDL cholesterol lower; HDL and triglycerides unchanged. PubMed PMID: 38688104
3. Olson BH, Anderson SM, Becker MP, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. The Journal of nutrition. 1997;127(10):1973-80. — 12 cereal trials, 404 adults; LDL 9% lower; lead author at a cereal manufacturer. PubMed PMID: 9311953
4. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. The American journal of clinical nutrition. 1999;69(1):30-42. — 67 trials; soluble fibres from oat, psyllium and pectin lower cholesterol by similar small amounts. PubMed PMID: 9925120
5. Schoeneck M, Iggman D. The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2021;31(5):1325-1338. — umbrella review; soluble-fibre foods including psyllium graded high-certainty LDL reducers. PubMed PMID: 33762150
6. Williams PG. The benefits of breakfast cereal consumption: a systematic review of the evidence base. Advances in nutrition (Bethesda, Md.). 2014;5(5):636S-673S. — oat-, barley- or psyllium-based cereals graded A for lowering cholesterol. PubMed PMID: 25225349
7. Brum J, Ramsey D, McRorie J, et al. Meta-Analysis of Usefulness of Psyllium Fiber as Adjuvant Antilipid Therapy to Enhance Cholesterol Lowering Efficacy of Statins. The American journal of cardiology. 2018;122(7):1169-1174. — 3 trials; psyllium plus statin lowered cholesterol more than statin alone; industry co-authors. PubMed PMID: 30078477
8. McRorie JW Jr, McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. Journal of the Academy of Nutrition and Dietetics. 2017;117(2):251-264. — viscosity of gel-forming fibres explains the cholesterol effect. PubMed PMID: 27863994
9. Xiao Z, Chen H, Zhang Y, et al. The effect of psyllium consumption on weight, body mass index, lipid profile, and glucose metabolism in diabetic patients: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytotherapy research : PTR. 2020;34(6):1237-1247. — 8 trials in diabetes; triglycerides and LDL lower; very high heterogeneity. PubMed PMID: 31919936
10. Sartore G, Reitano R, Barison A, et al. The effects of psyllium on lipoproteins in type II diabetic patients. European journal of clinical nutrition. 2009;63(10):1269-71. — 40 people with type 2 diabetes; triglycerides fell only in the psyllium group. PubMed PMID: 19623196
11. Clark CCT, Salek M, Aghabagheri E, et al. The effect of psyllium supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. The Korean journal of internal medicine. 2020;35(6):1385-1399. — 11 trials; systolic blood pressure 2.04 mmHg lower. PubMed PMID: 32066221
12. Juhász AE, Greff D, Teutsch B, et al. Galactomannans are the most effective soluble dietary fibers in type 2 diabetes: a systematic review and network meta-analysis. The American journal of clinical nutrition. 2023;117(2):266-277. — 46 trials in type 2 diabetes; galactomannans ranked first for LDL and triglycerides. PubMed PMID: 36811560

PubMed Topic Searches

1. Psyllium and LDL cholesterol meta-analyses
2. Psyllium with statins
3. Psyllium and bile acid excretion
4. Psyllium and apolipoprotein B

Back to Table of Contents

Connections

• Psyllium (Plantago ovata) — the main page
• Psyllium: Benefits Deep Dive — the evidence hub
• Blood Sugar and Diabetes — the companion metabolic article
• IBS, Constipation and Diarrhoea — the gut uses
• Allergy, Choking and Drug Timing — the choking warning that comes with the claim
• Digestive and Gut Herbs — the category
• Plantain: Its Psyllium Relatives — why plantain leaf does not lower cholesterol
• Cholesterol Management — medicines and diet together
• Lipid Panel — what LDL, HDL and non-HDL mean
• Cholesterol and Lipoproteins — an animation of how cholesterol travels
• Bile Acids and Fat Digestion — the cycle psyllium interrupts
• Oats: Beta-Glucan and Cholesterol — the other fibre with an FDA claim
• Barley — another beta-glucan source
• Fenugreek: Cholesterol — a galactomannan fibre
• Hypertension — the blood-pressure context

Back to Table of Contents